PR Newswire
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies
PLEASANTON, Calif.
, Oct. 29, 2025 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of the next generation of its high-performance Flex assay, featuring automation-compatible plate-based multiplexing. The new assay delivers cost-effective, highly scalable single cell analysis, empowering researchers to explore a broad range of studies – from high cell-number applications like functional genomics CRISPR screens to high-sample number applications like FFPE-based translational studies. With this assay, scientists can uncover new insights at scale and drive discoveries that were previously out of reach.
With the new assay, researchers can now profile up to 384 samples and 100 million cells per week using a 96-well plate format that integrates seamlessly with 10x’s automated cell partitioning for reliable, high-quality results. Built on 10x’s proven Flex chemistry, the assay delivers exceptional sensitivity and sequencing efficiency in a scalable workflow. Its automation-compatible, plate-based multiplexing supports modular usage, enabling greater experimental flexibility and scale while reducing reagent waste – delivering more data at lower cost and extending single cell analysis to studies that previously relied on bulk methods.
“As we increase scalability and ease of use, researchers are unlocking more – more samples, more conditions, more insights – at a fraction of the previous cost. And as AI-driven approaches evolve, the need for high-quality biological data is only accelerating,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “This next generation of Flex represents a transformational step forward in enabling large scale, foundational and translational studies, as well as routine single cell use.”
Early access customers have begun using new Flex across a range of discovery and translational research programs.
“Single cell technologies have transformed our understanding of human health and disease. However, traditional single cell multi-omics approaches have typically profiled only thousands of cells per experiment, making it difficult to scale or capture the complex dynamics that underpin our immune response to disease,” said Peter Skene, Senior Director, High Resolution Immunology at the Allen Institute. “The new 384-plex Flex assay from 10x Genomics is a game changer – enabling the profiling of millions of cells at a fraction of the cost. By fixing cells for batching and ensuring compatibility with liquid-handling automation, we can now explore functional immune responses with unprecedented depth and precision.”
“The next generation of the Flex assay delivers 10x’s most streamlined and robust single cell profiling to date,” said Stephen Christensen, Senior Principal Scientist, Immunology at Pfizer. “The ability to multiplex entire studies and process them in less time will be a powerful enabler for accelerating drug discovery and development.”
New Flex is now available globally. For more information, visit 10xgenomics.com or contact your 10x Genomics representative.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics’ products. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-the-next-generation-of-chromium-flex-to-empower-scientists-to-massively-scale-single-cell-research-302597705.html
SOURCE 10x Genomics, Inc.
